当前位置: 首页 > 期刊 > 《中国医药科学》 > 2013年第24期
编号:13144878
常用抗肿瘤药物基因组学研究进展(4)
http://www.100md.com 2013年12月15日 《中国医药科学》 2013年第24期
     [16] Pullarkat S,Stoehlmacher J,Ghaderi V,et al.Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy[J].Pharmacogenomics,2001,1:65-70.

    [17] Lecomte T,Ferraz J,Zinzindohoue F,et al.Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy[J]. Clin Cancer Res,2004,10:5880-5888.

    [18] Etienne-Grimaldi M,Francoual M,Formento J,et al. Methylenetetrahydrofolate reductase (MTHFR) variants and fluorouracil-based treatments in colorectal cancer[J].Pharmacogenomics,2007,8:1561-1566.

    [19] Fleming R,Milano G,Thyss A,et al.Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients[J].Cancer Res,1992,52:2899-2902.

    [20] Iyer L,King C,Whitington P,et al.Genetic predisposition to the metabolism of irinotecan (CPT-11).Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes[J].J Clin Invest,1998,101:847-854.

    (收稿日期:2013-10-02), http://www.100md.com(郝志英 李云娥)
上一页1 2 3 4